A headshot photo of James J. Mahoney III.

James J. Mahoney III, PhD

Associate Professor/Clinical Neuropsychologist

Contact Information

930 Chestnut Ridge Road
Morgantown, WV 26505


  • Behavioral Medicine & Psychiatry
  • Department of Neuroscience
  • Rockefeller Neuroscience Institute

Graduate Training

  • University of Houston, Ph.D. in Counseling Psychology
  • Pepperdine University (Los Angeles, CA), M.A.


  • Clinical Neuropsychology Internship - University of Oklahoma Health Sciences Center
  • Clinical Neuropsychology Fellowship - University of Virginia

Research Interests



Research Interests


My specific areas of research focus includes cognitive sequelae related to substance use as well as the investigation of various forms of neuromodulation, including deep brain stimulation, focused ultrasound, and transcranial magnetic stimulation for the treatment of substance use disorders. My current interests emerged from my previous research work as a Clinical Research Manager at the University of California, Los Angeles and the Baylor College of Medicine where the primary focus of the laboratories was Phase I medication development for stimulant use disorders. During this time, while the primary outcomes of the clinical trials were safety and initial efficacy of the medications, I was able to carve out my own niche that included evaluating whether these compounds impacted cognition as some of these agents had cognitive enhancing properties.


Research Topics:


  1. Investigating Novel Treatments for Substance Use Disorder
  2. Neuropsychological Sequelae Associated with Substance Use Disorder


Research Topics:

  1. Investigating Novel Treatments for Opioid Use Disorder
  2. Neuropsychological Sequelae Associated with Opioid Use Disorder



Mahoney JJ, Miller LE, Haut MW. Chapter 38: Substance abuse, prescribed medications, and toxin exposure. In: Boyle GJ, Stern Y, Stein DJ, Sahakian BJ, Golden CJ, Lee TMC, Chen SHA (eds), The SAGE Handbook of Clinical Neuropsychology: Clinical Neuropsychological Disorder 2024. SAGE Publications Ltd. ISBN: 9781529717754


Mahoney JJ 3rd, Finomore VS, Marton JL, Ramadan J, Hodder SL, Thompson-Lake DGY, Marsh CB, Koch-Gallup N, Ranjan M, Rezai AR. Identifying biomarkers of drug use recurrence using wearable device technologies and phone applications. Drug Alcohol Depend 2023;249:110817. PMID: 37331302. PMCID: PMC10416187. DOI: 10.1016/j.drugalcdep.2023.110817

Mahoney JJ, Haut MW, Carpenter J, Ranjan M, Thompson-Lake DGY, Marton JL, Zheng W, Berry JH, Tirumalai P, Mears A, D’Haese P, Finomore VS, Hodder SL, Rezai AR. Low-intensity focused ultrasound targeting the nucleus accumbens as a potential treatment for substance use disorder: safety and feasibility clinical trial. Frontiers in Psychiatry 2023;14. DOI: 10.3389/fpsyt.2023.1211566

Mahoney JJ 3rd, Thompson-Lake DGY, Ranjan M, Marton JL, Carpenter JS, Zheng W, Berry JH, Farmer DL, D'Haese P, Finomore VS, Tirumalai P, Mears AS, Suffridge J, Ames A, Hodder SL, Rezai AR. Low-Intensity Focused Ultrasound Targeting the Bilateral Nucleus Accumbens as a Potential Treatment for Substance Use Disorder: A First-in-Human Report. Biol Psychiatry 2023. Epub ahead of print. PMID: 37610405. DOI: 10.1016/j.biopsych.2023.06.031

Mahoney JJ 3rd, Winstanley EL, Castillo F, Luba r, Marton J, Alschuler DM, Liu Y, Comer SD. A pilot study investigating cognitive impairment associated with opioid overdose. Drug and Alcohol Dependence 2023;247:109865. PMID: 37094488. PMCID: PMC10230403. DOI: 10.1016/j.drugalcdep.2023.109865

Muksuris K, Scarisbrick DM, Mahoney JJ 3rd, Cherkasova MV. Noninvasive Neuromodulation in Parkinson's Disease: Insights from Animal Models. J Clin Med 2023;12(17):5448. PMID: 37685514. PMCID: PMC10487610. DOI: 10.3390/jcm12175448

Perle JG, Perle AR, Scarisbrick DM, Mahoney JJ 3rd. A Preliminary Investigation of Telehealth-Focused Supervision in Clinical Psychology Pre-doctoral Internships and Post-doctoral Fellowships Before and After the Onset of COVID-19. Journal of Technology in Behavioral Science 2023. DOI: 10.1007/s41347-023-00353-y

Rezai AR, Mahoney JJ, Ranjan M, Haut MW, Zheng W, Lander LR, Berry JH, Farmer DL, Marton JL, Tirumalai P, Mears A, Thompson-Lake DGY, Finomore VS, D'Haese PF, Aklin WM, George DT, Corrigan JD, Hodder SL. Safety and feasibility clinical trial of nucleus accumbens deep brain stimulation for treatment-refractory opioid use disorder. Journal of Neurosurgery 2023:1-9. Epub ahead of print. PMID: 37329519. DOI: 10.3171/2023.4.JNS23114


Mahoney JJ 3rd, Koch-Gallup N, Scarisbrick DM, Berry JH, Rezai AR. Deep brain stimulation for psychiatric disorders and behavioral/cognitive-related indications: Review of the literature and implications for treatment. J Neurol Sci 2022;437:120253. PMID: 35460949. DOI: 10.1016/j.jns.2022.120253

Perle JG, Perle AR, Scarisbrick DM, Mahoney JJ 3rd. Educating for the Future: a Preliminary Investigation of Doctoral-Level Clinical Psychology Training Program's Implementation of Telehealth Education. J Technol Behav Sci 2022;7(3):351-357. PMID: 35382354. PMCID: PMC8972773. DOI: 10.1007/s41347-022-00255-5

Perle JG, Perle AR, Scarisbrick DM, Mahoney JJ 3rd. Fostering telecompetence: A descriptive evaluation of clinical psychology predoctoral internship and postdoctoral fellowship implementation of telehealth education. J Rural Health 2022. PMID: 36042001. DOI: 10.1111/jrh.12709


Mahoney JJ, Haut MW, Hodder SL, Zheng W, Lander LR, Berry JH, Farmer DL, Marton JL, Ranjan M, Brandmeir NJ, Finomore VS, Hensley JL, Aklin WM, Wang GJ, Tomasi D, Shokri-Kojori E, Rezai AR. Deep brain stimulation of the nucleus accumbens/ventral capsule for severe and intractable opioid and benzodiazepine use disorder. Experimental and Clinical Psychopharmacology 2021;29(2):210-5. PMID: 34043402. DOI: 10.1037/pha0000453

Mahoney JJ, Winstanley EL, Lander LR, Berry JH, Marshalek PJ, Haut MW, Marton JL, Kimble WD, Armistead, Wen S, Cai Y, Hodder SL. High prevalence of co-occurring substance use in individuals with opioid use disorder. Addictive Behaviors 2021;114:106752. PMID: 33348147. DOI: 10.1016/j.addbeh.2020.106752

Reilly SE, Soulliard ZA, McCuddy WT, Mahoney JJ. Frequency and perceived effectiveness of mental health providers’ coping strategies during COVID-19. Current Psychology 2021;1-10. PMID: 33867779. PMCID: PMC8041948. DOI: 10.1007/s12144-021-01683-x

Winstanley EL, Mahoney JJ 3rd, Castillo F, Comer SD. Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review. Drug and Alcohol Dependence 2021;226:108838. PMID: 34271512. DOI: 10.1016/j.drugalcdep.2021.108838

Zane KL, McCuddy WT, Mahoney III JJ, Kelty MK, Scarisbrick DM. Assessing Psychometrists' Practices to Inform Neuropsychological Services. Arch Clin Neuropsychol 2021;36(5):693-701. PMID: 33316054. PMCID: PMC8292924. DOI: 10.1093/arclin/acaa122

Zane KL, Thaler NS, Reilly SE, Mahoney JJ 3rd, Scarisbrick DM. Neuropsychologists' practice adjustments: The impact of COVID-19. Clin Neuropsychol 2021;35(3):490-517. PMID: 33371799. PMCID: PMC8381282. DOI: 10.1080/13854046.2020.1863473


Research Manuscripts (Peer-Reviewed)

*Abbreviated list from 68 total peer-reviewed published manuscripts

Complete List of Published Works: https://www.ncbi.nlm.nih.gov/myncbi/189OsqqAyVeQS/bibliography/public/


  1. Mahoney, III, J.J., Kalechstein, A.D., De Marco, A.P., Newton, T.F. & De La Garza, II, R. (2017). The relationship between premorbid IQ and neurocognitive functioning in individuals with cocaine use disorders. Neuropsychology, 31, 311-318.

  2. Mahoney, III, J.J., Bajo, S.D., De Marco, A.P., Arredondo, B.C. & Broshek, D. K. (2017). Referring providers’ preferences and satisfaction with neuropsychological services. Archives of Clinical Neuropsychology, 32, 427-436.

  3. Mahoney, III, J.J., Haile, C.N., De La Garza, II, R., Thakkar, H., & Newton, T.F. (2017). Electrocardiographic characteristics in individuals with cocaine use disorder. American Journal on Addictions, 26, 221-227.

  4. Mahoney, III, J.J., Kalechstein, A.D., Newton, T.F. & De La Garza, II, R. (2017). The limited impact that cocaine use patterns have on neurocognitive functioning in individuals with cocaine use disorder. Journal of Psychopharmacology, 31, 989-995.

  5. Mahoney, III, J.J. (2019). Cognitive Dysfunction in Individuals with Cocaine Use Disorder: Potential Moderating Factors and Pharmacological Treatments. Experimental and Clinical Psychopharmacology, 27, 203-214.

  6. Mahoney, III, J.J., Marshalek, P.J., Rezai, A., Lander, L.R., Berry, J.H., & Haut, M.W. (2020). A Case Report Illustrating the Effects of Repetitive Transcranial Magnetic Stimulation on Cue-Induced Craving in an Individual with Opioid and Cocaine Use Disorder. Experimental and Clin. Psychopharmacology, 28, 1-5.

  7. Mahoney, III, J.J., Hanlon, C.A., Marshalek, P.J., Rezai, A., & Krinke, L. (2020). Transcranial Magnetic Stimulation, Deep Brain Stimulation, and Other Forms of Neuromodulation for Substance Use Disorders: Review of Modalities and Implications for Treatment. Journal of Neurological Sciences, 418, 117149.

  8. Mahoney, III, J.J., Winstanley, E., Lander, L.R., Berry, J.H., Marshalek, P.J., Haut, M.W., Marton, J., Kimble, W., Armistead, M., Wen, S., Cai, Y., & Hodder, S. (2020). High Prevalence of Co-Occurring Substance Use in Opioid Use Disorder.  Addictive Behaviors. 114, 106752.

  9. Mahoney, III, J.J., Haut, M., Hodder, S., Zheng, W., Lander, L., Berry, J., Farmer, D.L., Marton, J.L., Brandmeir, N., Ranjan, M., Finomore, V., Hensley, J.L., Aklin, W.M., Wang, G., Tomasi, D., Shokri-Kojori, E., & Rezai, A. (2021). Deep Brain Stimulation of the Nucleus Accumbens/Ventral Capsule for Co-occurring Opioid and Benzodiazepine Use Disorder. Experimental and Clinical Psychopharmacology, 29, 210-215.

  10. Mahoney, III, J.J., Koch-Gallup, N., Scarisbrick, D.M., & Rezai, A.R. (2022). Deep Brain Stimulation for Psychiatric Disorders and Behavioral/Cognitive-Related Indications: Review of the Literature and Implications for Treatment. Journal of Neurological Sciences, 437, 120253.